VLPONC-01 / VLP Therapeutics - LARVOL DELTA

Phase 1 study of VLPONC-01, a novel IL-12–encoding saRNA viral replicon particle, alone and in combination with pembrolizumab in head and neck cancer patients: Protocol summary. (ASCO 2026) - P1 | "The study includes two cohorts: Cohort A tests weekly intratumoral injection in recurrent and/or metastatic tumor patients to assess safety and determine dose levels, while Cohort C randomizes patients with resectable tumors into three groups to receive low-dose VLPONC-01 plus pembrolizumab, high-dose VLPONC-01 plus pembrolizumab, or pembrolizumab alone, prior to surgery. Outcomes include dose-limiting toxicities, surgical delays, systemic cytokine responses, and tumor response assessed by imaging and pathology."

Clinical • Combination therapy • First-in-human • P1 data • CNS Disorders • Gene Therapies • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • IL12A